<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.3 20210610//EN" "JATS-journalpublishing1-3.dtd">
<article article-type="research-article" dtd-version="1.3" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="ru"><front><journal-meta><journal-id journal-id-type="publisher-id">cardio</journal-id><journal-title-group><journal-title xml:lang="ru">Кардиология</journal-title><trans-title-group xml:lang="en"><trans-title>Kardiologiia</trans-title></trans-title-group></journal-title-group><issn pub-type="ppub">0022-9040</issn><issn pub-type="epub">2412-5660</issn><publisher><publisher-name>Kardiomag</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.18087/cardio.2608</article-id><article-id custom-type="elpub" pub-id-type="custom">cardio-810</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="ru"><subject>ОРИГИНАЛЬНЫЕ СТАТЬИ</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="en"><subject>RESEARCH ARTICLES</subject></subj-group></article-categories><title-group><article-title>Клинико-прогностическое значение резидуальной активности тромбоцитов у больных ОКС без подъемов сегмента ST</article-title><trans-title-group xml:lang="en"><trans-title>Clinical and prognostic value of the residual activity of platelets in patients with acute coronary syndrome without st segment elevation</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Стойко</surname><given-names>О. А.</given-names></name><name name-style="western" xml:lang="en"><surname>Stoyko</surname><given-names>O. A.</given-names></name></name-alternatives><bio xml:lang="ru"><p>625023, Тюмень, ул. Котовского, д. 55</p></bio><bio xml:lang="en"><p>Kotovskogo 55, Tyumen 625023</p></bio><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Шалаев</surname><given-names>С. В.</given-names></name><name name-style="western" xml:lang="en"><surname>Shalaev</surname><given-names>S. V.</given-names></name></name-alternatives><bio xml:lang="ru"><p>625023, Тюмень, ул. Одесская, д. 54</p></bio><bio xml:lang="en"><p>Tyumen, 625023, Odesskaya str. 54</p></bio><xref ref-type="aff" rid="aff-2"/></contrib></contrib-group><aff-alternatives id="aff-1"><aff xml:lang="ru"><institution>ГБУЗ ТО «ОКБ №1»</institution><country>Россия</country></aff><aff xml:lang="en"><institution>Regional Clinical Hospital #1 of Tyumen Region</institution><country>Russian Federation</country></aff></aff-alternatives><aff-alternatives id="aff-2"><aff xml:lang="ru"><institution>ФГБОУ ВО «Тюменский ГМУ» МЗ РФ</institution><country>Россия</country></aff><aff xml:lang="en"><institution>Tyumen State Medical University</institution><country>Russian Federation</country></aff></aff-alternatives><pub-date pub-type="collection"><year>2019</year></pub-date><pub-date pub-type="epub"><day>23</day><month>08</month><year>2019</year></pub-date><volume>59</volume><issue>7S</issue><fpage>40</fpage><lpage>46</lpage><permissions><copyright-statement>Copyright &amp;#x00A9; Kardiomag, 2019</copyright-statement><copyright-year>2019</copyright-year><copyright-holder xml:lang="ru">Kardiomag</copyright-holder><copyright-holder xml:lang="en">Kardiomag</copyright-holder><license xlink:href="https://cardio.elpub.ru/jour/about/submissions#copyrightNotice" xlink:type="simple"><license-p>https://cardio.elpub.ru/jour/about/submissions#copyrightNotice</license-p></license></permissions><self-uri xlink:href="https://cardio.elpub.ru/jour/article/view/810">https://cardio.elpub.ru/jour/article/view/810</self-uri><abstract><p>Цель исследования. В условиях длительного наблюдения оценить клинико-прогностическое значение резидуальной активности тромбоцитов у больных острым коронарным синдромом без подъема сегмента ST (ОКСбпST). Материалы и методы.В исследование включили 120 пациентов с ОКСбпST, подвергшихся стентированию коронарных артерий (КА). Агрегацию тромбоцитов оценивали методом импедансометрии после назначения нагрузочных доз аспирина и P2Y12-блокатора тромбоцитов. Больных разделили на две сопоставимые по полу и возрасту группы: с низкой остаточной реактивностью тромбоцитов (НОРТ) от 0 до 5 Ом (n=90) и с высокой остаточной реактивностью тромбоцитов (ВОРТ) ≥6 Ом, (n=30). Разделение проведено согласно полученным результатам референсных значений в контрольной группе добровольцев. Проведена сравнительная оценка клинико-лабораторных и инструментальных показателей, а также частоты развития комбинированной конечной точки (ишемических событий) и кровотечений в период наблюдения – в среднем в течение 16±6 месяцев. Результаты. Пациенты с ВОРТ были исходно тяжелее, в группе чаще регистрировались больные со стенокардией напряжения III функционального класса, фибрилляцией предсердий, перенесенным инфарктом миокарда, у них был выше сердечно-сосудистый риск по шкале GRACE (202,6±11 и 148,6±7, р=0,03), чаще регистрировались повышение уровня тропонина Т в крови (70,0 и 45,5%, р=0,02), а также острая окклюзия в КА (66,6% и 42,2, р=0,02). Развитие комбинированной конечной точки, включавшей сердечнососудистую смерть, госпитализации в связи с острым коронарным синдромом, ишемическим инсультом в период наблюдения у пациентов с ВОРТ, регистрировалось чаще (40 и 20,7%, р=0,04). У пациентов с АДФ-агрегацией тромбоцитов 0 и 1 Ом включительно был выше риск развития геморрагических событий, по сравнению с больными с АДФ-агрегацией от 2 Ом и выше (17,1 и 2,1%, относительный риск 8,05; 95% доверительный интервал: 1,1–59,9, р=0,01). Заключение. Сохранение ВОРТ после нагрузочных доз аспирина и P2Y12-блокатора тромбоцитов у больных ОКСбпSTассоциировалась с развитием повторных атеротромботических событий. Крайне низкие показатели резидуальной агрегации тромбоцитов ассоциировались с бÓльшей частотой развития кровотечений.</p></abstract><trans-abstract xml:lang="en"><p>Aim. To study clinical prognostic value of residual platelet activity in patients with acute coronary syndrome without ST segment elevation. Material and methods. The study included 120 patients with acute coronary syndrome without ST segment elevation (NSTE ACS) with coronary artery stenting. Testing of residual reactivity of platelets in the subjects was carried out after loading doses of  aspirin and P2Y12-inhibitors.Patients were divided into two groups comparable in gender and age: with low residual reactivity of platelets (LRR), n=90 and with high residual reactivity of platelets (HRR), n=30. Between the groups a comparative assessment of clinical-laboratory and instrumental indicators, development of a combined end point (ischemic events) and bleeding during follow-up (16 ± 6 months). Results. The group with HRR was initially heavier: patients with angina pectoris of functional class III, atrial fibrillation, myocardial infarction, was a higher risk on the GRACE (202,6±11 vs. 148,6±7, р=0,03),increased levels of Troponin T (70,0 vs. 45,5%, р=0,02), acute occlusion in the coronary arteries (66,6 vs. 42,4%, р=0,02).The combined endpoint was more often reported in patients with HRR (40 vs. 20,7%, р=0,04). Patients with ADP-aggregation of platelets in the range 0–1 Om had a greater risk of developing hemorrhagic events (17,1 vs. 2,1%, RR 8,05 CI: 1,1–59,9, р=0,01). Conclusion. In patients with NSTE ACSHRR after loading doses of aspirin and P2Y12-inhibitor was associated with the development of repeated atherothrombotic events. Very low LRR was associated with the development of bleeding.</p></trans-abstract><kwd-group xml:lang="ru"><kwd>острый коронарный синдром без подъема сегмента ST</kwd><kwd>функциональная активность тромбоцитов</kwd><kwd>чрескожное коронарное вмешательство</kwd><kwd>двойная антитромбоцитарная терапия</kwd></kwd-group><kwd-group xml:lang="en"><kwd>acute coronary syndrome without ST segment elevation</kwd><kwd>functional activity of platelets</kwd><kwd>transcutaneous coronary intervention</kwd><kwd>double antiplatelet therapy</kwd></kwd-group></article-meta></front><back><ref-list><title>References</title><ref id="cit1"><label>1</label><citation-alternatives><mixed-citation xml:lang="ru">Windecker S, Kolh P, Alfonso F, Collet JP, Cremer J, Falk V et al. 2014 ESC/EACTS Guidelines on myocardial revascularization: The Task Force on Myocardial Revascularization of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS)Developed with the special contribution of the European Association of Percutaneous Cardiovascular Interventions (EAPCI). European Heart Journal. 2014;35(37):2541–619. DOI: 10.1093/eurheartj/ehu278</mixed-citation><mixed-citation xml:lang="en">Windecker S, Kolh P, Alfonso F, Collet JP, Cremer J, Falk V et al. 2014 ESC/EACTS Guidelines on myocardial revascularization: The Task Force on Myocardial Revascularization of the European Society of Cardiology (ESC) and the European Association for Cardio-Thoracic Surgery (EACTS)Developed with the special contribution of the European Association of Percutaneous Cardiovascular Interventions (EAPCI). European Heart Journal. 2014;35(37):2541–619. DOI: 10.1093/eurheartj/ehu278</mixed-citation></citation-alternatives></ref><ref id="cit2"><label>2</label><citation-alternatives><mixed-citation xml:lang="ru">Gratsiansky N.A. Antiplatelet therapy for coronary heart disease. Some challenges and achievements. Atherothrombosis. 2010;1:2–86. [Russian: Грацианский Н.А. Антитромбоцитарная терапия при коронарной болезни сердца. Некоторые проблемы и достижения. Атеротромбоз. 2010;1:2-86]</mixed-citation><mixed-citation xml:lang="en">Gratsiansky N.A. Antiplatelet therapy for coronary heart disease. Some challenges and achievements. Atherothrombosis. 2010;1:2–86. [Russian: Грацианский Н.А. Антитромбоцитарная терапия при коронарной болезни сердца. Некоторые проблемы и достижения. Атеротромбоз. 2010;1:2-86]</mixed-citation></citation-alternatives></ref><ref id="cit3"><label>3</label><citation-alternatives><mixed-citation xml:lang="ru">Sibbing D, Byrne RA, Bernlochner I, Kastrati A. High platelet reactivity and clinical outcome – Fact and fiction. Thrombosis and Haemostasis. 2011;106(08):191–202. DOI: 10.1160/TH11-01-0040</mixed-citation><mixed-citation xml:lang="en">Sibbing D, Byrne RA, Bernlochner I, Kastrati A. High platelet reactivity and clinical outcome – Fact and fiction. Thrombosis and Haemostasis. 2011;106(08):191–202. DOI: 10.1160/TH11-01-0040</mixed-citation></citation-alternatives></ref><ref id="cit4"><label>4</label><citation-alternatives><mixed-citation xml:lang="ru">Breet NJ. Comparison of Platelet Function Tests in Predicting Clinical Outcome in Patients Undergoing Coronary Stent Implantation. JAMA. 2010;303(8):754–62. DOI: 10.1001/jama.2010.181</mixed-citation><mixed-citation xml:lang="en">Breet NJ. Comparison of Platelet Function Tests in Predicting Clinical Outcome in Patients Undergoing Coronary Stent Implantation. JAMA. 2010;303(8):754–62. DOI: 10.1001/jama.2010.181</mixed-citation></citation-alternatives></ref><ref id="cit5"><label>5</label><citation-alternatives><mixed-citation xml:lang="ru">Tantry US, Bonello L, Aradi D, Price MJ, Jeong Y-H, Angiolillo DJ et al. Consensus and Update on the Definition of On-Treatment Platelet Reactivity to Adenosine Diphosphate Associated with Ischemia and Bleeding. Journal of the American College of Cardiology. 2013;62(24):2261–73. DOI: 10.1016/j.jacc.2013.07.101</mixed-citation><mixed-citation xml:lang="en">Tantry US, Bonello L, Aradi D, Price MJ, Jeong Y-H, Angiolillo DJ et al. Consensus and Update on the Definition of On-Treatment Platelet Reactivity to Adenosine Diphosphate Associated with Ischemia and Bleeding. Journal of the American College of Cardiology. 2013;62(24):2261–73. DOI: 10.1016/j.jacc.2013.07.101</mixed-citation></citation-alternatives></ref><ref id="cit6"><label>6</label><citation-alternatives><mixed-citation xml:lang="ru">Aradi D, Storey RF, Komócsi A, Trenk D, Gulba D, Kiss RG et al. Expert position paper on the role of platelet function testing in patients undergoing percutaneous coronary intervention. European Heart Journal. 2014;35(4):209–15. DOI: 10.1093/eurheartj/eht375</mixed-citation><mixed-citation xml:lang="en">Aradi D, Storey RF, Komócsi A, Trenk D, Gulba D, Kiss RG et al. Expert position paper on the role of platelet function testing in patients undergoing percutaneous coronary intervention. European Heart Journal. 2014;35(4):209–15. DOI: 10.1093/eurheartj/eht375</mixed-citation></citation-alternatives></ref><ref id="cit7"><label>7</label><citation-alternatives><mixed-citation xml:lang="ru">Stone GW, Witzenbichler B, Weisz G, Rinaldi MJ, Neumann F-J, Metzger DC et al. Platelet reactivity and clinical outcomes after coronary artery implantation of drug-eluting stents (ADAPT-DES): a prospective multicentre registry study. The Lancet. 2013;382(9892):614–23. DOI: 10.1016/S0140-6736(13)61170-8</mixed-citation><mixed-citation xml:lang="en">Stone GW, Witzenbichler B, Weisz G, Rinaldi MJ, Neumann F-J, Metzger DC et al. Platelet reactivity and clinical outcomes after coronary artery implantation of drug-eluting stents (ADAPT-DES): a prospective multicentre registry study. The Lancet. 2013;382(9892):614–23. DOI: 10.1016/S0140-6736(13)61170-8</mixed-citation></citation-alternatives></ref><ref id="cit8"><label>8</label><citation-alternatives><mixed-citation xml:lang="ru">Alekyan B.G., Abugov S.A., Andreev D.A., Buryachkovskaya L.I., Vavilova T.V., Vershinina M.G. et al. The role of platelet functional activity testing in the prevention of cardiovascular complications in patients receiving antiplatelet therapy. Rational Pharmacotherapy in Cardiology. 2014;10(6):679–87. [Russian: Алекян Б.Г., Абугов С.А., Андреев Д.А., Бурячковская Л.И., Вавилова Т.В., Вершинина М.Г. и др. Роль тестирования функциональной активности тромбоцитов в профилактике сердечно-сосудистых осложнений у больных, получающих антитромбоцитарную терапию. Рациональная Фармакотерапия в Кардиологии. 2014;10(6):679-87]</mixed-citation><mixed-citation xml:lang="en">Alekyan B.G., Abugov S.A., Andreev D.A., Buryachkovskaya L.I., Vavilova T.V., Vershinina M.G. et al. The role of platelet functional activity testing in the prevention of cardiovascular complications in patients receiving antiplatelet therapy. Rational Pharmacotherapy in Cardiology. 2014;10(6):679–87. [Russian: Алекян Б.Г., Абугов С.А., Андреев Д.А., Бурячковская Л.И., Вавилова Т.В., Вершинина М.Г. и др. Роль тестирования функциональной активности тромбоцитов в профилактике сердечно-сосудистых осложнений у больных, получающих антитромбоцитарную терапию. Рациональная Фармакотерапия в Кардиологии. 2014;10(6):679-87]</mixed-citation></citation-alternatives></ref><ref id="cit9"><label>9</label><citation-alternatives><mixed-citation xml:lang="ru">Roffi M, Patrono C, Collet J-P, Mueller C, Valgimigli M, Andreotti F et al. 2015 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: Task Force for the Management of Acute Coronary Syndromes in Patients Presenting without Persistent ST-Segment Elevation of the European Society of Cardiology (ESC). European Heart Journal. 2016;37(3):267–315. DOI: 10.1093/eurheartj/ehv320</mixed-citation><mixed-citation xml:lang="en">Roffi M, Patrono C, Collet J-P, Mueller C, Valgimigli M, Andreotti F et al. 2015 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: Task Force for the Management of Acute Coronary Syndromes in Patients Presenting without Persistent ST-Segment Elevation of the European Society of Cardiology (ESC). European Heart Journal. 2016;37(3):267–315. DOI: 10.1093/eurheartj/ehv320</mixed-citation></citation-alternatives></ref><ref id="cit10"><label>10</label><citation-alternatives><mixed-citation xml:lang="ru">Mehran R, Rao SV, Bhatt DL, Gibson CM, Caixeta A, Eikelboom J et al. Standardized Bleeding Definitions for Cardiovascular Clinical Trials: A Consensus Report from the Bleeding Academic Research Consortium. Circulation. 2011;123(23):2736–47. DOI: 10.1161/CIRCULATIONAHA.110.009449</mixed-citation><mixed-citation xml:lang="en">Mehran R, Rao SV, Bhatt DL, Gibson CM, Caixeta A, Eikelboom J et al. Standardized Bleeding Definitions for Cardiovascular Clinical Trials: A Consensus Report from the Bleeding Academic Research Consortium. Circulation. 2011;123(23):2736–47. DOI: 10.1161/CIRCULATIONAHA.110.009449</mixed-citation></citation-alternatives></ref><ref id="cit11"><label>11</label><citation-alternatives><mixed-citation xml:lang="ru">Cannon CP, Harrington RA, James S, Ardissino D, Becker RC, Emanuelsson H et al. Comparison of ticagrelor with clopidogrel in patients with a planned invasive strategy for acute coronary syndromes (PLATO): a randomised double-blind study. The Lancet. 2010;375(9711):283–93. DOI: 10.1016/S0140-6736(09)62191-7</mixed-citation><mixed-citation xml:lang="en">Cannon CP, Harrington RA, James S, Ardissino D, Becker RC, Emanuelsson H et al. Comparison of ticagrelor with clopidogrel in patients with a planned invasive strategy for acute coronary syndromes (PLATO): a randomised double-blind study. The Lancet. 2010;375(9711):283–93. DOI: 10.1016/S0140-6736(09)62191-7</mixed-citation></citation-alternatives></ref><ref id="cit12"><label>12</label><citation-alternatives><mixed-citation xml:lang="ru">Gurbel PA, Bliden KP, Butler K, Antonino MJ, Wei C, Teng R et al. Response to Ticagrelor in Clopidogrel Nonresponders and Responders and Effect of Switching Therapies: The RESPOND Study. Circulation. 2010;121(10):1188–99. DOI: 10.1161/CIRCULATIONAHA.109.919456</mixed-citation><mixed-citation xml:lang="en">Gurbel PA, Bliden KP, Butler K, Antonino MJ, Wei C, Teng R et al. Response to Ticagrelor in Clopidogrel Nonresponders and Responders and Effect of Switching Therapies: The RESPOND Study. Circulation. 2010;121(10):1188–99. DOI: 10.1161/CIRCULATIONAHA.109.919456</mixed-citation></citation-alternatives></ref><ref id="cit13"><label>13</label><citation-alternatives><mixed-citation xml:lang="ru">Mega JL, Simon T, Collet J-P, Anderson JL, Antman EM, Bliden K et al. ReducedFunction CYP2C19 Genotype and Risk of Adverse Clinical Outcomes Among Patients Treated with Clopidogrel Predominantly for PCI: A Meta-analysis. JAMA. 2010;304(16):1821–30. DOI: 10.1001/jama.2010.1543</mixed-citation><mixed-citation xml:lang="en">Mega JL, Simon T, Collet J-P, Anderson JL, Antman EM, Bliden K et al. ReducedFunction CYP2C19 Genotype and Risk of Adverse Clinical Outcomes Among Patients Treated with Clopidogrel Predominantly for PCI: A Meta-analysis. JAMA. 2010;304(16):1821–30. DOI: 10.1001/jama.2010.1543</mixed-citation></citation-alternatives></ref><ref id="cit14"><label>14</label><citation-alternatives><mixed-citation xml:lang="ru">Frelinger AL, Bhatt DL, Lee RD, Mulford DJ, Wu J, Nudurupati S et al. Clopidogrel Pharmacokinetics and Pharmacodynamics Vary Widely Despite Exclusion or Control of Polymorphisms (CYP2C19, ABCB1, PON1), Noncompliance, Diet, Smoking, Co-Medications (Including Proton Pump Inhibitors), and Pre-Existent Variability in Platelet Function. Journal of the American College of Cardiology. 2013;61(8):872–9. DOI: 10.1016/j.jacc.2012.11.040</mixed-citation><mixed-citation xml:lang="en">Frelinger AL, Bhatt DL, Lee RD, Mulford DJ, Wu J, Nudurupati S et al. Clopidogrel Pharmacokinetics and Pharmacodynamics Vary Widely Despite Exclusion or Control of Polymorphisms (CYP2C19, ABCB1, PON1), Noncompliance, Diet, Smoking, Co-Medications (Including Proton Pump Inhibitors), and Pre-Existent Variability in Platelet Function. Journal of the American College of Cardiology. 2013;61(8):872–9. DOI: 10.1016/j.jacc.2012.11.040</mixed-citation></citation-alternatives></ref><ref id="cit15"><label>15</label><citation-alternatives><mixed-citation xml:lang="ru">Yusuf S, Fox KA, Tognoni G, Mehta SR. Effects of Clopidogrel in Addition to Aspirin in Patients with Acute Coronary Syndromes without ST-Segment Elevation. New England Journal of Medicine. 2001;345(7):494–502. DOI: 10.1056/NEJMoa010746</mixed-citation><mixed-citation xml:lang="en">Yusuf S, Fox KA, Tognoni G, Mehta SR. Effects of Clopidogrel in Addition to Aspirin in Patients with Acute Coronary Syndromes without ST-Segment Elevation. New England Journal of Medicine. 2001;345(7):494–502. DOI: 10.1056/NEJMoa010746</mixed-citation></citation-alternatives></ref><ref id="cit16"><label>16</label><citation-alternatives><mixed-citation xml:lang="ru">Udell JA, Bonaca MP, Collet J-P, Lincoff AM, Kereiakes DJ, Costa F et al. Long-term dual antiplatelet therapy for secondary prevention of cardiovascular events in the subgroup of patients with previous myocardial infarction: a collaborative meta-analysis of randomized trials. European Heart Journal. 2015;37(4):390–9. DOI: 10.1093/eurheartj/ehv443</mixed-citation><mixed-citation xml:lang="en">Udell JA, Bonaca MP, Collet J-P, Lincoff AM, Kereiakes DJ, Costa F et al. Long-term dual antiplatelet therapy for secondary prevention of cardiovascular events in the subgroup of patients with previous myocardial infarction: a collaborative meta-analysis of randomized trials. European Heart Journal. 2015;37(4):390–9. DOI: 10.1093/eurheartj/ehv443</mixed-citation></citation-alternatives></ref><ref id="cit17"><label>17</label><citation-alternatives><mixed-citation xml:lang="ru">Yusuf S, Attaran A, Bosch J, Joseph P, Lonn E, McCready T et al. Combination pharmacotherapy to prevent cardiovascular disease: present status and challenges. European Heart Journal. 2014;35(6):353–64. DOI: 10.1093/eurheartj/eht407</mixed-citation><mixed-citation xml:lang="en">Yusuf S, Attaran A, Bosch J, Joseph P, Lonn E, McCready T et al. Combination pharmacotherapy to prevent cardiovascular disease: present status and challenges. European Heart Journal. 2014;35(6):353–64. DOI: 10.1093/eurheartj/eht407</mixed-citation></citation-alternatives></ref><ref id="cit18"><label>18</label><citation-alternatives><mixed-citation xml:lang="ru">Stone GW, Maehara A, Lansky AJ, de Bruyne B, Cristea E, Mintz GS et al. A Prospective Natural-History Study of Coronary Atherosclerosis. New England Journal of Medicine. 2011;364(3):226–35. DOI: 10.1056/NEJMoa1002358</mixed-citation><mixed-citation xml:lang="en">Stone GW, Maehara A, Lansky AJ, de Bruyne B, Cristea E, Mintz GS et al. A Prospective Natural-History Study of Coronary Atherosclerosis. New England Journal of Medicine. 2011;364(3):226–35. DOI: 10.1056/NEJMoa1002358</mixed-citation></citation-alternatives></ref><ref id="cit19"><label>19</label><citation-alternatives><mixed-citation xml:lang="ru">Matetzky S, Shenkman B, Guetta V, Shechter M, Beinart R, Goldenberg I et al. Clopidogrel Resistance Is Associated with Increased Risk of Recurrent Atherothrombotic Events in Patients With Acute Myocardial Infarction. Circulation. 2004;109(25):3171–5. DOI: 10.1161/01.CIR.0000130846.46168.03</mixed-citation><mixed-citation xml:lang="en">Matetzky S, Shenkman B, Guetta V, Shechter M, Beinart R, Goldenberg I et al. Clopidogrel Resistance Is Associated with Increased Risk of Recurrent Atherothrombotic Events in Patients With Acute Myocardial Infarction. Circulation. 2004;109(25):3171–5. DOI: 10.1161/01.CIR.0000130846.46168.03</mixed-citation></citation-alternatives></ref><ref id="cit20"><label>20</label><citation-alternatives><mixed-citation xml:lang="ru">Snoep JD, Hovens MMC, Eikenboom JCJ, van der Bom JG, Jukema JW, Huisman MV. Clopidogrel nonresponsiveness in patients undergoing percutaneous coronary intervention with stenting: A systematic review and meta-analysis. American Heart Journal. 2007;154(2):221–31. DOI: 10.1016/j.ahj.2007.04.014</mixed-citation><mixed-citation xml:lang="en">Snoep JD, Hovens MMC, Eikenboom JCJ, van der Bom JG, Jukema JW, Huisman MV. Clopidogrel nonresponsiveness in patients undergoing percutaneous coronary intervention with stenting: A systematic review and meta-analysis. American Heart Journal. 2007;154(2):221–31. DOI: 10.1016/j.ahj.2007.04.014</mixed-citation></citation-alternatives></ref></ref-list><fn-group><fn fn-type="conflict"><p>The authors declare that there are no conflicts of interest present.</p></fn></fn-group></back></article>
